Medial EarlySign develops an AI algorithmic platform for the discovery of clinical insights that indicate the likelihood of disease from basic medical information, such as blood test results, and other EMR data. Called AlgoMarkers, its predictive engines are built in collaboration with healthcare organizations, through the combination of 10s of millions of patient years-worth of data, clinical rigor and some of the most brilliant algorithmic minds. The company develops clinical decision support and population health solutions that can assist in the early prediction of clinical outcomes related to cancers, metabolic, immune and infectious diseases. These tools are designed to place at the fingertips of healthcare organizations only those insights that could prove critical in disease management and prevention empowering them with proactive, predictive and personalized care management capabilities

The product is offered to health providers and health plans as a platform to engage, motivate and activate their at-risk patients/members to enable discharges to home, follow up from ER visits, closing care gaps and slowing, preventing or managing the onset of chronic diseases from metabolic conditions. Developed on a leading conversational AI platform that supports voice and text patient interactions with YODHA chat bot on smart phones and desktops. The product integrates patient data from EMR and claims records with information that is gathered in structured chat interactions to tailor personalized engagement strategies that align with the health care organizations patient engagement goals.